Atypical Antipsychotics for Irritability in Pediatric Autism: A Systematic Review and Network Meta-Analysis
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Irritability is common in pediatric autism spectrum disorder (ASD) patients. This can have major implications in child development, receptivity to behavioral therapy, as well as child and caregiver well-being. A systematic review and network meta-analysis were conducted to assess the efficacy and safety of atypical antipsychotics in treating irritability in these patients. METHODS: Studies were identified from Medline, Embase, and PsycINFO from inception to March 2018. The clinical trials database was reviewed. Studies were included if they were a double-blind, randomized controlled trial utilizing the Aberrant Behavior Checklist Irritability (ABC-I) to measure the efficacy of atypical antipsychotic monotherapy. Data extraction was carried out following the Preferred Reporting Items for Systematic Reviews and Meta-analyses for network meta-analysis guidelines. The main outcome was the reduction in irritability score using the ABC-I subscale from baseline. RESULTS: Eight trials comparing four interventions-risperidone, aripiprazole, lurasidone, and placebo in 878 patients, were included. Both risperidone and aripiprazole had significantly reduced ABC-I scores than placebo. Estimates of mean differences (95% credible intervals) were risperidone, -6.89 (-11.14, -2.54); aripiprazole, -6.62 (-10.88, -2.22); and lurasidone, -1.61 (-9.50, 6.23). Both risperidone and aripiprazole had similar safety. There were only eight studies included in the analysis, however, sample sizes were not small. Variance in reporting of adverse effects limited the quality of safety analysis. CONCLUSION: Risperidone and aripiprazole were the two best drugs, with comparable efficacy and safety in pediatric ASD patients. These two medications could be beneficial in improving irritability in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baio, J., Wiggins, L., Christensen, D. L., Maenner, M. J., Daniels, J., Warren, Z., Kurzius-Spencer, M., Zahorodny, W., Robinson, C., Rosenberg, et al. (2018) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss6706a1 · Cited by 6,078 · cited 1×
“The Centers for Disease Control estimates that * 1 in 59 children have been diagnosed with this disorder in the United States, with incidences occurring in all socioeconomic, ethnic, and racial groups (Baio et al. 2018).”
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 2×
“Consistency between direct and indirect evidence was assessed using the node-split method (Dias et al. 2010).”
InfluentialRisperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · cited 3×
“Five trials were conducted in the United States (McCracken et al. 2002; Marcus et al. 2009; Owen et al. 2009; Kent et al. 2013; Loebel et al. 2016), one in Canada (Shea et al. 2004), one in Japan (Ichikawa et al. 2017), and one in Iran (Ghanizadeh et al. 2014).”
Dias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013) · Medical Decision Making · doi:10.1177/0272989x12458724 · Cited by 1,207
Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613 · cited 3×
“Five trials were conducted in the United States (McCracken et al. 2002; Marcus et al. 2009; Owen et al. 2009; Kent et al. 2013; Loebel et al. 2016), one in Canada (Shea et al. 2004), one in Japan (Ichikawa et al. 2017), and one in Iran (Ghanizadeh et al. 2014).”
Lecavalier, L. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0147-5 · Cited by 569 · cited 1×
“Moderate to severe irritability alone is found in * 20% of ASD patients (Lecavalier 2006).”
A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J. (2011) · Pediatrics · doi:10.1542/peds.2011-0427 · Cited by 356 · cited 1×
“Behavioral interventions to treat antecedents, alter environments, and support parents in management of impulsivity and aggression are preferred, but in highly aggressive or persistently irritable youth, medications are often important interventions (McPheeters et al. 2011).”
Emotion dysregulation and the Core features of autism Spectrum disorder
Samson, A. C., Phillips, J. M., Parker, K. J., Shah, S., Gross, J. J., & Hardan, A. Y. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-2022-5 · Cited by 338 · cited 1×
“Irritability can impede quality of life, familial and community interactions, the implementation of interventional therapies, as well as long-term outcomes (Samson et al. 2014; Fung et al. 2016).”
Fung, L. K., Mahajan, R., Nozzolillo, A., Bernal, P., Krasner, A., Jo, B., Coury, D., Whitaker, A., Veenstra-Vanderweele, J., & Hardan, A. Y. (2016) · Pediatrics · doi:10.1542/peds.2015-2851k · Cited by 294
Use of psychotropic medication in children and adolescents with autism spectrum disorders
Coury, D. L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., McCoy, R., Whitaker, A., & Perrin, J. M. (2012) · PEDIATRICS · doi:10.1542/peds.2012-0900d · Cited by 191 · cited 1×
“A data-base analysis of 2853 pediatric ASD patients found that 27% of pediatric ASD patients were receiving at least one psychotropic medication (Coury et al. 2012).”
Ghanizadeh, A., Sahraeizadeh, A., & Berk, M. (2014) · Child Psychiatry & Human Development · doi:10.1007/s10578-013-0390-x · Cited by 134
Cognitive Effects of Risperidone in Children with Autism and Irritable Behavior
Aman, M. G., Hollway, J. A., McDougle, C. J., Scahill, L., Tierney, E., McCracken, J. T., Arnold, L. E., Vitiello, B., Ritz, L., Gavaletz, A., et al. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0133 · Cited by 80 · cited 1×
“A double-blinded study of risperidone, in children ages 5–17, demonstrated no apparent detrimental impairment of cognitive or academic ability in doses up to 3.5mg for 8 weeks (Aman et al. 2008).”
Cited by
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Lai, M.-C., Anagnostou, E., Wiznitzer, M., Allison, C., & Baron-Cohen, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30034-x · Cited by 250
Linden, A., Best, L., Elise, F., Roberts, D., Branagan, A., Tay, Y. B. E., Crane, L., Cusack, J., Davidson, B., Davidson, I., et al. (2023) · Autism · doi:10.1177/13623613221117931 · Cited by 78
Yuge, K., Nagamitsu, S., Ishikawa, Y., Hamada, I., Takahashi, H., Sugioka, H., Yotsuya, O., Mishima, K., Hayashi, M., & Yamashita, Y. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02847-y · Cited by 57
On Behalf of the ISACA Guideline Working Group, D’Alò, G. L., De Crescenzo, F., Amato, L., Cruciani, F., Davoli, M., Fulceri, F., Minozzi, S., Mitrova, Z., Morgano, G. P., et al. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01669-0 · Cited by 54
Metadata
- Authors
- Fallah, M. S., Shaikh, M. R., Neupane, B., Rusiecki, D., Bennett, T. A., & Beyene, J.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2019-04
- Volume
- 29
- Issue
- 3
- Pages
- 168-180
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2911380759
- Cited by
- 115
- References
- 13
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.